Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1986 1
1988 1
1989 1
1991 1
1993 2
1994 1
2010 2
2011 5
2012 3
2013 5
2014 3
2015 10
2016 12
2017 20
2018 18
2019 25
2020 19
2021 30
2022 17
2023 16
2024 24
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
EGFR signaling pathway as therapeutic target in human cancers.
Levantini E, Maroni G, Del Re M, Tenen DG. Levantini E, et al. Among authors: del re m. Semin Cancer Biol. 2022 Oct;85:253-275. doi: 10.1016/j.semcancer.2022.04.002. Epub 2022 Apr 12. Semin Cancer Biol. 2022. PMID: 35427766 Review.
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).
Gouda MA, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdel Karim N, De Miguel Perez D, Del Re M, Russo A, Curigliano G, Rolfo C, Subbiah V. Gouda MA, et al. Among authors: del re m. Ann Oncol. 2024 Mar;35(3):267-275. doi: 10.1016/j.annonc.2023.12.007. Epub 2023 Dec 23. Ann Oncol. 2024. PMID: 38145866 Free article. Review.
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. Among authors: del re m. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
Facing an un-met need in lung cancer screening: The never smokers.
Arrieta O, Arroyo-Hernández M, Soberanis-Piña PD, Viola L, Del Re M, Russo A, de Miguel-Perez D, Cardona AF, Rolfo C. Arrieta O, et al. Among authors: del re m. Crit Rev Oncol Hematol. 2024 Oct;202:104436. doi: 10.1016/j.critrevonc.2024.104436. Epub 2024 Jul 6. Crit Rev Oncol Hematol. 2024. PMID: 38977146 Review.
Understanding EGFR heterogeneity in lung cancer.
Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E, Fumagalli C, Pisapia P, Pepe F, De Luca C, Cucchiara F, Troncone G, Danesi R, Spaggiari L, De Marinis F, Rolfo C. Passaro A, et al. Among authors: del re m. ESMO Open. 2020 Oct;5(5):e000919. doi: 10.1136/esmoopen-2020-000919. ESMO Open. 2020. PMID: 33067323 Free PMC article. Review.
Clinical pharmacology of intravitreal anti-VEGF drugs.
Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Fogli S, et al. Among authors: del re m. Eye (Lond). 2018 Jun;32(6):1010-1020. doi: 10.1038/s41433-018-0021-7. Epub 2018 Feb 5. Eye (Lond). 2018. PMID: 29398697 Free PMC article. Review.
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data.
Giordano G, Griguolo G, Landriscina M, Meattini I, Carbone F, Leone A, Del Re M, Fogli S, Danesi R, Colamaria A, Dieci MV. Giordano G, et al. Among authors: del re m. Crit Rev Oncol Hematol. 2023 Dec;192:104185. doi: 10.1016/j.critrevonc.2023.104185. Epub 2023 Oct 18. Crit Rev Oncol Hematol. 2023. PMID: 37863404 Free article. Review.
195 results